Randomized controlled trial of brain-derived neurotrophic factor in Guillain–Barré syndrome: a pilot study
Article first published online: 15 JAN 2010
European Journal of Neurology
Volume 7, Issue 4, pages 423–426, July 2000
How to Cite
Bensa, S., Hadden, R. D. M., Hahn, A., Hughes, R. A. C. and Willison, H. J. (2000), Randomized controlled trial of brain-derived neurotrophic factor in Guillain–Barré syndrome: a pilot study. European Journal of Neurology, 7: 423–426. doi: 10.1046/j.1468-1331.2000.00096.x
- Issue published online: 15 JAN 2010
- Article first published online: 15 JAN 2010
- Received 3 June 1999Accepted 9 March 2000
- brain-derived neurotrophic factor;
- Guillain–Barré syndrome
Brain-derived neurotrophic factor (BDNF) has the theoretical potential to protect neurones from axonal degeneration. The objective of this study was to discover whether brain-derived neurotrophic factor is safe in Guillain–Barré syndrome, and to make preliminary observations of its efficacy. This was a parallel group randomized controlled trial of subcutaneous brain-derived neurotrophic factor 25 µg/kg daily compared with placebo for up to 24 weeks or until patients could walk without aid.
Six patients received brain-derived neurotrophic factor, of whom three had serious adverse events including one death. Four patients received placebo, of whom two had serious adverse events including one death. The rate and extent of recovery were similar in the two groups.
This pilot study did not detect any serious adverse events attributed to brain-derived neurotrophic factor treatment.